Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients.
HIV-positive patients are at increased risk of developing adenovirus infection, particularly of the gastrointestinal tract and with unusual subgenus D strains. To investigate humoral immunity to these strains of adenoviruses, the humoral immune response was examined in longitudinal samples of serum against isolates collected from a prospective study of HIV-positive patients with subgenus D adenovirus infection. Of 10 HIV-positive patients developing adenovirus infection, 3 had chronic infection (8->27 months) with one serotype, 3 had chronic infection (>/=10 months) with changing serotypes and 4 had acute and self-limiting adenovirus infection (<1 month). Fifty-one sera were tested, and samples collected before adenovirus infection were available in 8 patients. Neutralising assays were performed against the patient's own isolate (adenoviruses 9, 17, 19, 19/23, 19/37, 23, 26, 23/26, 43 and 46) and common circulating strains of adenovirus 1-5. Indirect immunofluorescence tests were carried out against the autologous isolate and complement-fixation tests were undertaken using a standard assay. Immunofluorescence test antibodies were detected (titre >/=160) in all patients, and present to high titre (>/=320) in 8/10 patients. Complement-fixing antibodies were not detected in significant titre. Of particular note, there was no significant neutralising antibody response to the patient's own isolate after acute infection. Neutralising antibody to adenovirus 3 (titre 20) was transiently detected in two patients. In the remaining patients neutralising antibody directed against adenoviruses 1-5 was not detected. Persistent carriage of subgenus D adenoviruses in HIV-positive patients is probably the result of failure of cell-mediated immune responses to clear primary infection. Nevertheless, there is marked impairment of B cell responses resulting in poor neutralising and complement-fixing antibody production even though immunofluorescence test determined antibodies are produced in high titre. These possibly reflect impairment of effective B cell priming mechanisms within the germinal centres of lymph nodes, or the polyclonal activation of B cells driven by HIV infection.
Lord
A
A
Clinical Virology, Manchester Royal Infirmary, Manchester, United Kingdom.
Bailey
A S
AS
Klapper
P E
PE
Snowden
N
N
Khoo
S H
SH
D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000276:immunology* / Q000821:virology; D000258:Adenovirus Infections, Human / Q000097:blood / Q000150:complications / Q000276:immunology* / Q000821:virology; D000260:Adenoviruses, Human / Q000276:immunology / Q000302:isolation & purification; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D003168:Complement Fixation Tests; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D009500:Neutralization Tests; D011446:Prospective Studies
D000914:Antibodies, Viral